CYTARABINE Side Effects

7023652-9 | Febrile Neutropenia, Klebsiella Test Positive, Sepsis
on Sep 29, 2010 Female patient from UNITED STATES , weighting 30.42 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, klebsiella test positive, sepsis (What is sepsis?). Cytarabine dosage: 4200 Mg. Patient was hospitalized.

7017990-3 | Blood Pressure Fluctuation, Grand Mal Convulsion, Reversible Posterior Leukoencephalopathy Syndrome
Patient was taking Cytarabine (View Usage). Patient had the following side effects: blood pressure fluctuation, grand mal convulsion, reversible posterior leukoencephalopathy syndrome on Sep 14, 2010 from TURKEY Additional patient health information: Male patient , child 11 years of age, was diagnosed with t-cell type acute leukaemia and. Cytarabine dosage: Intrathecal. During the same period patient was treated with METHOTREXATE (5 G/m^2 Per 24 Hours) (View Methotrexate Review and Methotrexate Label ), PREDNISONE (Intrathecal) (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

7017965-4 | Blood Pressure Increased, Grand Mal Convulsion, Hallucination, Visual, Reversible Posterior Leukoencephalopathy Syndrome, Vasogenic Cerebral Oedema
Adverse event was reported on Sep 14, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: Intrathecal) was diagnosed with t-cell type acute leukaemia and. Location: TURKEY , child 12 years of age, After Cytarabine was administered, patient had the following side effects: blood pressure increased, grand mal convulsion, hallucination, visual, reversible posterior leukoencephalopathy syndrome, vasogenic cerebral oedema. During the same period patient was treated with METHOTREXATE (5 G/m^2 Per 24 Hours, Intravenous Drip, Intrathecal) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE SULFATE (1.5 M/m 2 Milligram(s)/sq. Meter) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DEXAMETHASONE (20 Mg/m 2 Milligram(s)/ Sq. Meter, Oral) (View Dexamethasone Review and Dexamethasone Label ), PREDNISONE (Intrathecal) (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

7017957-5 | Convulsion, Headache, Hypertension, Reversible Posterior Leukoencephalopathy Syndrome, Speech Disorder
on Sep 14, 2010 Male patient from TURKEY , child 12 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion, headache (What is headache?), hypertension, reversible posterior leukoencephalopathy syndrome, speech disorder. Cytarabine dosage: Intrathecal. During the same period patient was treated with METHOTREXATE (5 G/m^2, Intravenous Drip, Intrathecal) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (1.5 Mg/m^2) (View Vincristine Review and Vincristine Label ), DEXAMETHASONE (20 Mg/m 2 Milligram(s)/sq. Meter) (View Dexamethasone Review and Dexamethasone Label ), PREDNISONE (Intrathecal) (View Prednisone Review and Prednisone Label ). Patient was hospitalized.


7008080-4 | Alanine Aminotransferase Increased, Bacterial Infection, Febrile Neutropenia, Hepatic Candidiasis, Hepatic Lesion, Hepatitis Acute, Hepatitis B Surface Antigen Positive
on Sep 08, 2010 Female patient from TURKEY , 57 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Cytarabine (View Usage). Patient had the following side effects: alanine aminotransferase increased, bacterial infection (What is bacterial infection?), febrile neutropenia, hepatic candidiasis, hepatic lesion, hepatitis acute, hepatitis b surface antigen positive. Cytarabine dosage: 75 Mg/m2 Milligram (s)/sq. Meter, 500 Mg/m 2 Milligram(s) /sq. Meter. During the same period patient was treated with METHOTREXATE (12 Mg Milligram(s) Intrathecal) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE SULFATE (1.5 Mg/m 2 Milligram(s)/sq. Meter) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DAUNORUBICIN HCL (25 Mg/m 2 Milligram(s) Sq. Meter) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), PREDNISOLONE (60 Mg/m 2 Milligram(s) Sq. Meter) (View Prednisolone Review and Prednisolone Label ), ELSPAR (5000 U/m^2/day) (View Elspar Review and Elspar Label ), CYCLOPHOSPHAMIDE (650 Mg/m 2 Milligram(s) Sq. Meter) (View Cyclophosphamide Review and Cyclophosphamide Label ), MERCAPTOPURINE (60 Mg/m 2 Milligram(s)/sq. Meter) (View Mercaptopurine Review and Mercaptopurine Label ), MITOXANTRONE (12 Mg/m 2 Milligram(s)/sq. Meter) (View Mitoxantrone Review and Mitoxantrone Label ). Patient was hospitalized.

7002682-7 | Abdominal Compartment Syndrome, Abdominal Distension, Blood Culture Positive, Candidiasis, Diet Refusal, Duodenal Ulcer, Duodenitis, Enterococcal Infection, Pneumonia
Patient was taking Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: abdominal compartment syndrome, abdominal distension, blood culture positive, candidiasis, diet refusal, duodenal ulcer, duodenitis, enterococcal infection, pneumonia (What is pneumonia?) on Sep 17, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 16.09 lb, . Cytarabine dosage: 253 Mg. During the same period patient was treated with DAUNORUBICIN HCL (14 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), DEXAMETHASONE (30.3 Mg) (View Dexamethasone Review and Dexamethasone Label ), HYDROCORTISONE (28 Mg) (View Hydrocortisone Review and Hydrocortisone Label ), L ASPARAGINASE (13350 Mg) (View L-asparaginase Review and L-asparaginase Label ), METHOTREXATE (14 Mg) (View Methotrexate Review and Methotrexate Label ), PREDNISONE (90 Mg) (View Prednisone Review and Prednisone Label ), VINCRISTINE SULFATE (1.2 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6994550-1 | Febrile Neutropenia, Streptococcal Bacteraemia
Adverse event was reported on Sep 15, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 41580 Mg) . Location: UNITED STATES , weighting 233.2 lb, Patient experienced the following unwanted or unexpected effects: febrile neutropenia, streptococcal bacteraemia. Patient was hospitalized.

6994543-4 | Abdominal Pain, Diarrhoea, Febrile Neutropenia, Gastrointestinal Disorder, Gastrointestinal Oedema, Pyrexia
on Sep 15, 2010 Male patient from UNITED STATES , weighting 216.7 lb, was treated with Cytarabine (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), diarrhoea, febrile neutropenia, gastrointestinal disorder, gastrointestinal oedema, pyrexia. Cytarabine dosage: 36800 Mg. During the same period patient was treated with ETOPOSIDE (3360 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6986089-4 | Hepatitis B
on Sep 01, 2010 Male patient from TURKEY , 59 years of age, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: hepatitis b (What is hepatitis b?). Cytarabine dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), LAMIVUDINE (100 Mg Milligram (s) (day)) (View Lamivudine Review and Lamivudine Label ).

6970158-9 | Cellulitis, Dermatitis Bullous, Haemoglobin Decreased, Neutropenia, Palmar-plantar Erythrodysaesthesia Syndrome, Platelet Count Decreased, Rash Erythematous, Rash Pruritic, Skin Exfoliation
Patient was taking Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: cellulitis (What is cellulitis?), dermatitis bullous, haemoglobin decreased, neutropenia, palmar-plantar erythrodysaesthesia syndrome, platelet count decreased, rash erythematous, rash pruritic, skin exfoliation on Aug 24, 2010 from TURKEY Additional patient health information: Male patient , child 12 years of age, was diagnosed with acute lymphocytic leukaemia and. Cytarabine dosage: 4 G/m^2,. During the same period patient was treated with METHOTREXATE (1 G/m^2; Intravenous Drip) (View Methotrexate Review and Methotrexate Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), ELSPAR (View Elspar Review and Elspar Label ), THIOGUANINE (View Thioguanine Review and Thioguanine Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ). Patient was hospitalized.

6969495-3 | Blood Culture Positive, Febrile Neutropenia
Adverse event was reported on Sep 07, 2010 by a Female patient taking Cytarabine (View Usage) (Dosage: 31.5 G) . Location: UNITED STATES , weighting 149.7 lb, Patient had the following side effects: blood culture positive, febrile neutropenia. Patient was hospitalized.

6958409-8 | Neutropenia, Pyrexia
on Aug 30, 2010 Male patient from UNITED STATES , weighting 204.6 lb, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: neutropenia, pyrexia. Cytarabine dosage: 37.98 G. Patient was hospitalized.

6958391-3 | Appendicitis, Hypophosphataemia, Incision Site Pain
on Aug 30, 2010 Male patient from UNITED STATES , weighting 174.2 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: appendicitis (What is appendicitis?), hypophosphataemia, incision site pain. Cytarabine dosage: 1323 Mg. During the same period patient was treated with DAUNORUBICIN HCL (510 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (567 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6956505-2 | Hypomagnesaemia, Multi-organ Failure, Nausea, Sepsis, Wernicke-korsakoff Syndrome
Patient was taking Cytarabine (View Usage). Patient had the following side effects: hypomagnesaemia, multi-organ failure, nausea (What is nausea?), sepsis (What is sepsis?), wernicke-korsakoff syndrome on Aug 20, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 62 years of age, was diagnosed with central nervous system lymphoma, sepsis (What is sepsis?) and. Cytarabine dosage: . During the same period patient was treated with METHOTREXATE SODIUM (View Methotrexate Sodium Review and Methotrexate Sodium Label ), DOXYCYCLINE HYCLATE (View Doxycycline Hyclate Review and Doxycycline Hyclate Label ). Patient was hospitalized.

6947070-4 | Activities Of Daily Living Impaired, Demyelinating Polyneuropathy, Muscular Weakness
Adverse event was reported on Aug 17, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 6 G Gram(s), 1 Day, Intravenous) . Location: UNITED KINGDOM , 47 years of age, weighting 189.6 lb, After Cytarabine was administered, patient had the following side effects: activities of daily living impaired, demyelinating polyneuropathy, muscular weakness. During the same period patient was treated with ACYCLOVIR SODIUM (View Acyclovir Sodium Review and Acyclovir Sodium Label ), (AMBAZONE) (View (ambazone) Review and (ambazone) Label ), AZITHROMYCIN (View Azithromycin Review and Azithromycin Label ), (CASPOFUNGIN) (View (caspofungin) Review and (caspofungin) Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), (GABAPENTIN) (View (gabapentin) Review and (gabapentin) Label ), (LINEZOLID) (View (linezolid) Review and (linezolid) Label ), METRONIDAZOLE (View Metronidazole Review and Metronidazole Label ).

6940481-2 | Abdominal Pain, Bone Marrow Failure, Dizziness, Dyspnoea Exertional, Erosive Duodenitis, Gastrointestinal Haemorrhage, Hypoxia, Pallor, Pancytopenia
on Aug 06, 2010 Male patient from UNITED STATES , 71 years of age, was diagnosed with acute myeloid leukaemia and was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), bone marrow failure, dizziness (What is dizziness?), dyspnoea exertional, erosive duodenitis, gastrointestinal haemorrhage, hypoxia, pallor, pancytopenia. Cytarabine dosage: . During the same period patient was treated with NORVASC (View Norvasc Review and Norvasc Label ), NYSTATIN (View Nystatin Review and Nystatin Label ), POTASSIUM (POTASSIUM CHLORIDE) (View Potassium (potassium Chloride) Review and Potassium (potassium Chloride) Label ). Patient was hospitalized.

6937097-0 | Hypoxia, Respiratory Tract Infection Fungal
on Jul 28, 2010 Female patient from AUSTRALIA , 19 years of age, weighting 162.0 lb, was diagnosed with acute myeloid leukaemia, neutropenia and was treated with Cytarabine (View Usage). Patient had the following side effects: hypoxia, respiratory tract infection fungal. Cytarabine dosage: 6000 Mg, On Four Alternate Days, Intravenous. During the same period patient was treated with IDARUBICIN HCL (18 Mg, 1x/day Days 1-3, Intravenous) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), ETOPOSIDE (150 Mg, 1x/day For 7 Days, Intravenous) (View Etoposide Review and Etoposide Label ), NEULASTA (6 Mg, 1x/day, Subcutaneous) (View Neulasta Review and Neulasta Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6936293-6 | Hypomagnesaemia, Multi-organ Failure, Nausea, Sepsis, Wernicke-korsakoff Syndrome
Patient was taking Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: hypomagnesaemia, multi-organ failure, nausea (What is nausea?), sepsis (What is sepsis?), wernicke-korsakoff syndrome on Aug 13, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 62 years of age, was diagnosed with central nervous system lymphoma, sepsis (What is sepsis?) and. Cytarabine dosage: . During the same period patient was treated with METHOTREXATE SODIUM (View Methotrexate Sodium Review and Methotrexate Sodium Label ), DOXYCYCLINE HYCLATE (View Doxycycline Hyclate Review and Doxycycline Hyclate Label ). Patient was hospitalized.

6935769-5 | Febrile Neutropenia
Adverse event was reported on Aug 19, 2010 by a Female patient taking Cytarabine (View Usage) (Dosage: 35460 Mg) . Location: UNITED STATES , weighting 220.5 lb, Patient experienced the following unwanted or unexpected effects: febrile neutropenia. Patient was hospitalized.

6930370-1 | Cerebellar Syndrome, Confusional State, Hypomagnesaemia, Hypophagia, Multi-organ Failure, Nausea, Paraneoplastic Syndrome, Sepsis, Thrombocytopenia
on Aug 02, 2010 Female patient from UNITED KINGDOM , 62 years of age, was diagnosed with central nervous system lymphoma, sepsis (What is sepsis?) and was treated with Cytarabine (View Usage). Patient had the following side effects: cerebellar syndrome, confusional state, hypomagnesaemia, hypophagia, multi-organ failure, nausea (What is nausea?), paraneoplastic syndrome, sepsis (What is sepsis?), thrombocytopenia. Cytarabine dosage: . During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), DOXYCYCLINE (View Doxycycline Review and Doxycycline Label ), FUSIDIC ACID (View Fusidic Acid Review and Fusidic Acid Label ), VANCOMYCIN HYDROCHLORIDE (View Vancomycin Hydrochloride Review and Vancomycin Hydrochloride Label ).

6930369-5 | Febrile Neutropenia, No Therapeutic Response, Tuberculosis
on Aug 03, 2010 Male patient from TURKEY , 31 years of age, was diagnosed with acute myeloid leukaemia and was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: febrile neutropenia, no therapeutic response, tuberculosis (What is tuberculosis?). Cytarabine dosage: . Patient was hospitalized.

6929791-2 | Febrile Neutropenia, No Therapeutic Response, Tuberculosis
Patient was taking Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, no therapeutic response, tuberculosis (What is tuberculosis?) on Aug 03, 2010 from TURKEY Additional patient health information: Male patient , 30 years of age, was diagnosed with acute myeloid leukaemia and. Cytarabine dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ). Patient was hospitalized.

6927918-X | Caecitis, Febrile Neutropenia, Mucormycosis, Septic Shock
Adverse event was reported on Aug 05, 2010 by a Female patient taking Cytarabine (View Usage) (Dosage: Unk) was diagnosed with acute myeloid leukaemia and. Location: KOREA, REPUBLIC OF , 63 years of age, Patient had the following side effects: caecitis, febrile neutropenia, mucormycosis, septic shock. During the same period patient was treated with IDARUBICIN HCL (Unk) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), CEFTRIAXONE (Unk) (View Ceftriaxone Review and Ceftriaxone Label ), ITRACONAZOLE (Unk) (View Itraconazole Review and Itraconazole Label ).

6925834-0 | Abdominal Pain, Computerised Tomogram Abdomen Abnormal, Diarrhoea, Febrile Neutropenia, Gastrointestinal Oedema, Infection, Inflammation
on Aug 13, 2010 Male patient from UNITED STATES , weighting 216.7 lb, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), computerised tomogram abdomen abnormal, diarrhoea, febrile neutropenia, gastrointestinal oedema, infection (What is infection?), inflammation. Cytarabine dosage: 36800 Mg. During the same period patient was treated with ETOPOSIDE (3360 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6925595-5 | Aspergillus Test Positive, Hypoxia, Lung Disorder, Lung Infiltration, Pleural Effusion, Pulmonary Haemorrhage
on Aug 13, 2010 Female patient from CANADA , weighting 105.8 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: aspergillus test positive, hypoxia, lung disorder, lung infiltration, pleural effusion, pulmonary haemorrhage. Cytarabine dosage: 2030 Mg. During the same period patient was treated with DAUNORUBICIN HCL (261 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.

6924246-3 | Acidosis, Agitation, Bone Marrow Failure, Condition Aggravated, Hypercapnia, Hyperphosphataemia, Lung Neoplasm, Metabolic Disorder, Pneumonia
Patient was taking Cytarabine (View Usage). Patient had the following side effects: acidosis, agitation, bone marrow failure, condition aggravated, hypercapnia, hyperphosphataemia, lung neoplasm, metabolic disorder (What is metabolic disorder?), pneumonia (What is pneumonia?) on Aug 11, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 237.0 lb, . Cytarabine dosage: 645 Mg. During the same period patient was treated with DAUNORUBICIN HCL (388 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (430 Mg) (View Etoposide Review and Etoposide Label ).

6923230-3 | Hypomagnesaemia, Multi-organ Failure, Nausea, Sepsis, Wernicke-korsakoff Syndrome
Adverse event was reported on Aug 03, 2010 by a Female patient taking Cytarabine (View Usage) (Dosage: ) was diagnosed with central nervous system lymphoma, sepsis (What is sepsis?) and. Location: UNITED KINGDOM , 62 years of age, After Cytarabine was administered, patient had the following side effects: hypomagnesaemia, multi-organ failure, nausea (What is nausea?), sepsis (What is sepsis?), wernicke-korsakoff syndrome. During the same period patient was treated with METHOTREXATE SODIUM (View Methotrexate Sodium Review and Methotrexate Sodium Label ), DOXYCYCLINE HYCLATE (View Doxycycline Hyclate Review and Doxycycline Hyclate Label ). Patient was hospitalized.

6916713-3 | Appendicitis, Hypophosphataemia, Infection
on Aug 09, 2010 Male patient from UNITED STATES , weighting 174.2 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: appendicitis (What is appendicitis?), hypophosphataemia, infection (What is infection?). Cytarabine dosage: 1323 Mg. During the same period patient was treated with DAUNORUBICIN HCL (510 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (567 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6916686-3 | Pyrexia
on Aug 09, 2010 Male patient from UNITED STATES , weighting 30.20 lb, was treated with Cytarabine (View Usage). Patient had the following side effects: pyrexia. Cytarabine dosage: 50 Mg. During the same period patient was treated with DEXAMETHASONE (1.6 Mg) (View Dexamethasone Review and Dexamethasone Label ), METHOTREXATE (10 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE(PEGASPARGASE, ONCOSPAR) (1425 Unit) (View Peg-l-asparaginase(pegaspargase, Oncospar) Review and Peg-l-asparaginase(pegaspargase, Oncospar) Label ), VINCRISTINE SULFATE (.8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6915431-5 | Cardio-respiratory Arrest, Febrile Neutropenia, Nervous System Disorder, Pneumonia Aspiration, Respiratory Failure, Vomiting
Patient was taking Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: cardio-respiratory arrest, febrile neutropenia, nervous system disorder, pneumonia aspiration, respiratory failure, vomiting on Aug 06, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 141.1 lb, . Cytarabine dosage: 9600 Mg. During the same period patient was treated with IDARUBICIN HCL (57 Mg) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), PRAVASTATIN SODIUM (10240 Mg) (View Pravastatin Sodium Review and Pravastatin Sodium Label ).

6915188-8 | Cerebral Haemorrhage, Intracranial Pressure Increased, Intraventricular Haemorrhage, Leukaemic Infiltration Brain, Mental Status Changes, Subarachnoid Haemorrhage
Adverse event was reported on Aug 05, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 2860 Mg) . Location: UNITED STATES , weighting 209.0 lb, Patient experienced the following unwanted or unexpected effects: cerebral haemorrhage, intracranial pressure increased, intraventricular haemorrhage, leukaemic infiltration brain, mental status changes, subarachnoid haemorrhage. During the same period patient was treated with DAUNORUBICIN HCL (396 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.

6914442-3 | Diarrhoea, Hypotension, Malaise, Rash Maculo-papular
on Jul 28, 2010 Female patient from FRANCE , 67 years of age, was diagnosed with acute myeloid leukaemia and was treated with Cytarabine (View Usage). Patient had the following side effects: diarrhoea, hypotension, malaise, rash maculo-papular. Cytarabine dosage: Unk. During the same period patient was treated with ZAVEDOS (Unk) (View Zavedos Review and Zavedos Label ), BELUSTINE (Unk) (View Belustine Review and Belustine Label ), ZOPHREN (Unk) (View Zophren Review and Zophren Label ). Patient was hospitalized.

6913986-8 | Bacterial Sepsis, Pancytopenia
on Aug 05, 2010 Male patient from UNITED STATES , 60 years of age, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: bacterial sepsis, pancytopenia. Cytarabine dosage: . Patient was hospitalized.

6906240-1 | Antibiotic Resistant Staphylococcus Test Positive, Blood Urine Present, Culture Urine Positive, Neutropenia, Pyrexia, Thrombocytopenia
Patient was taking Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: antibiotic resistant staphylococcus test positive, blood urine present, culture urine positive, neutropenia, pyrexia, thrombocytopenia on Aug 03, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 212.1 lb, . Cytarabine dosage: 2432 Mg. During the same period patient was treated with ETOPOSIDE (16640 Mg) (View Etoposide Review and Etoposide Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), AMITRIPTYLINE HYDROCHLORIDE (View Amitriptyline Hydrochloride Review and Amitriptyline Hydrochloride Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), CYMBALTA (View Cymbalta Review and Cymbalta Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), FLUTICASONE PROPIONATE (View Fluticasone Propionate Review and Fluticasone Propionate Label ). Patient was hospitalized.

6906238-3 | Cerebral Haemorrhage, Intracranial Pressure Increased, Intraventricular Haemorrhage, Leukaemic Infiltration, Subarachnoid Haemorrhage
Adverse event was reported on Aug 03, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 2860 Mg) . Location: UNITED STATES , weighting 209.0 lb, Patient had the following side effects: cerebral haemorrhage, intracranial pressure increased, intraventricular haemorrhage, leukaemic infiltration, subarachnoid haemorrhage. During the same period patient was treated with DAUNORUBICIN HCL (396 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ).

6902000-6 | Chromaturia, Coagulopathy, Free Haemoglobin Present, Haemolysis, Oedema Peripheral, Pain In Extremity, Septic Shock, Skin Infection
on Aug 02, 2010 Female patient from UNITED STATES , weighting 127.9 lb, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: chromaturia, coagulopathy, free haemoglobin present, haemolysis, oedema peripheral, pain in extremity, septic shock, skin infection. Cytarabine dosage: 70 Mg. During the same period patient was treated with DAUNORUBICIN HCL (80 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.

6900491-8 | Leukoencephalopathy, Sensorimotor Disorder
on Jul 22, 2010 Female patient from FRANCE , 62 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: leukoencephalopathy, sensorimotor disorder. Cytarabine dosage: 1 Df, Cyclic. During the same period patient was treated with METHOTREXATE SODIUM (1 Df, Cyclic) (View Methotrexate Sodium Review and Methotrexate Sodium Label ), DEPO MEDROL (1 Df, Cyclic) (View Depo-medrol Review and Depo-medrol Label ), METHYLPREDNISOLONE (1 Df, Cyclic) (View Methylprednisolone Review and Methylprednisolone Label ), BICNU (1 Df, Cyclic) (View Bicnu Review and Bicnu Label ), ETOPOSIDE (1 Df, Cyclic) (View Etoposide Review and Etoposide Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), TEATROIS (View Teatrois Review and Teatrois Label ). Patient was hospitalized.

6882094-7 | Caecitis
Patient was taking Cytarabine (View Usage). Patient had the following side effects: caecitis on Jul 28, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 114.9 lb, . Cytarabine dosage: 1085 Mg. During the same period patient was treated with DAUNORUBICIN HCL (418.5 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (465 Mg) (View Etoposide Review and Etoposide Label ).

6874726-4 | Burning Sensation, Hypersensitivity, Pruritus
Adverse event was reported on Jul 14, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 5043mg, Daily, Intravenous) . Location: CANADA , 45 years of age, weighting 335.1 lb, After Cytarabine was administered, patient had the following side effects: burning sensation, hypersensitivity, pruritus. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), LIDOCAINE (View Lidocaine Review and Lidocaine Label ), ACETAMINOPHEN W/ CODEINE (View Acetaminophen W/ Codeine Review and Acetaminophen W/ Codeine Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), NYSTATIN (View Nystatin Review and Nystatin Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ).

6874614-3 | Bacterial Sepsis, Neutropenic Sepsis
on Jul 08, 2010 Female patient from UNITED KINGDOM , 73 years of age, was diagnosed with leukaemia and was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: bacterial sepsis, neutropenic sepsis. Cytarabine dosage: 100 Mg/m2 Milligram(s), Sq. Meter (2 Day). During the same period patient was treated with DAUNORUBICIN HCL (50 Ug/ M 2 Microgram(s) / Sq. Meter Intravenous) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.

6874511-3 | Chest Pain, Decreased Appetite, Dyspnoea, Fatigue, Headache, Nausea, Neutropenia, Peripheral Sensorimotor Neuropathy
on Jul 23, 2010 Male patient from UNITED STATES , weighting 216.1 lb, was treated with Cytarabine (View Usage). Patient had the following side effects: chest pain (What is chest pain?), decreased appetite, dyspnoea, fatigue, headache (What is headache?), nausea (What is nausea?), neutropenia, peripheral sensorimotor neuropathy. Cytarabine dosage: . During the same period patient was treated with MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ONCASPAR (View Oncaspar Review and Oncaspar Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6874414-4 | Caecitis
Patient was taking Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: caecitis on Jul 23, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 114.9 lb, . Cytarabine dosage: 1085 Mg. During the same period patient was treated with DAUNORUBICIN HCL (418.5 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (465 Mg) (View Etoposide Review and Etoposide Label ).

6868896-1 | Anaemia, Disseminated Intravascular Coagulation, Metabolic Acidosis, Neutropenia, Poor Peripheral Circulation, Pyrexia, Renal Failure, Respiratory Failure
Adverse event was reported on Jul 21, 2010 by a Female patient taking Cytarabine (View Usage) (Dosage: 19600 Mg) . Location: UNITED STATES , weighting 132.3 lb, Patient experienced the following unwanted or unexpected effects: anaemia, disseminated intravascular coagulation, metabolic acidosis, neutropenia, poor peripheral circulation, pyrexia, renal failure, respiratory failure. During the same period patient was treated with L ASPARAGINASE (125000 Mg) (View L-asparaginase Review and L-asparaginase Label ). Patient was hospitalized.

6865650-1 | Abdominal Pain Lower, Caecitis, Enterococcal Infection, Febrile Neutropenia, Haematochezia, Intestinal Dilatation, Mucormycosis, Mucosal Necrosis, Neutropenic Colitis
on Jul 06, 2010 Female patient from KOREA, REPUBLIC OF , 63 years of age, was diagnosed with acute myeloid leukaemia and was treated with Cytarabine (View Usage). Patient had the following side effects: abdominal pain lower, caecitis, enterococcal infection, febrile neutropenia, haematochezia, intestinal dilatation, mucormycosis, mucosal necrosis, neutropenic colitis. Cytarabine dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), CEFTRIAXONE (View Ceftriaxone Review and Ceftriaxone Label ), ITRACONAZOLE (View Itraconazole Review and Itraconazole Label ).

6843918-2 | Blood Creatinine Increased, Blood Urea Increased, Dilatation Ventricular, Electrocardiogram Qt Prolonged, Musculoskeletal Pain, Pericardial Effusion, Septic Shock, Ventricular Dyskinesia, Ventricular Hypokinesia
on Jul 14, 2010 Male patient from UNITED STATES , weighting 210.8 lb, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: blood creatinine increased, blood urea increased, dilatation ventricular, electrocardiogram qt prolonged, musculoskeletal pain, pericardial effusion, septic shock, ventricular dyskinesia, ventricular hypokinesia. Cytarabine dosage: 3670 Mg. During the same period patient was treated with ETOPOSIDE (1125 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6840348-4 | Neuropathy Peripheral
Patient was taking Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: neuropathy peripheral on Jul 06, 2010 from FRANCE Additional patient health information: Female patient , 64 years of age, was diagnosed with acute myeloid leukaemia and. Cytarabine dosage: 180 Mg Per Month (30 Mg Five Times Per Month). During the same period patient was treated with ZAVEDOS (Unk) (View Zavedos Review and Zavedos Label ), BELUSTINE (Unk) (View Belustine Review and Belustine Label ), XATRAL SLOW RELEASE (View Xatral - Slow Release Review and Xatral - Slow Release Label ), IMOVANE (View Imovane Review and Imovane Label ), ZOPHREN (View Zophren Review and Zophren Label ), DEROXAT (View Deroxat Review and Deroxat Label ).

6836248-6 | Febrile Neutropenia, Hepatic Steatosis, Irritability, Pneumoperitoneum, Small Intestinal Perforation
Adverse event was reported on Jul 13, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 70 Mg) . Location: CANADA , weighting 37.48 lb, Patient had the following side effects: febrile neutropenia, hepatic steatosis, irritability, pneumoperitoneum, small intestinal perforation. During the same period patient was treated with DAUNORUBICIN HCL (80 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), METHOTREXATE (12 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (K H) (2000 Iu) (View Peg-l- Asparaginase (k-h) Review and Peg-l- Asparaginase (k-h) Label ), PREDNISONE (1344 Mg) (View Prednisone Review and Prednisone Label ), VINCRISTINE SULFATE (4.6 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), CODEINE (View Codeine Review and Codeine Label ), FLAGYL (View Flagyl Review and Flagyl Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ). Patient was hospitalized.

6836242-5 | Brain Abscess, Cerebral Fungal Infection, Fatigue, Headache, Scedosporium Infection
on Jul 12, 2010 Male patient from UNITED STATES , weighting 232.6 lb, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: brain abscess, cerebral fungal infection, fatigue, headache (What is headache?), scedosporium infection. Cytarabine dosage: 70 Mg. During the same period patient was treated with DOXORUBICIN HYDROCHLORIDE (220 Mg) (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), METHOTREXATE (15 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (K H) (5500 Mg) (View Peg-l Asparaginase (k-h) Review and Peg-l Asparaginase (k-h) Label ), VINCRISTINE SULFATE (8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6836232-2 | Cardio-respiratory Arrest, Headache, Hypotension, Leukaemia Recurrent, Pain In Jaw, Pyrexia, Respiratory Failure
on Jul 12, 2010 Male patient from UNITED STATES , weighting 277.8 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: cardio-respiratory arrest, headache (What is headache?), hypotension, leukaemia recurrent, pain in jaw, pyrexia, respiratory failure. Cytarabine dosage: 34000 Mg. During the same period patient was treated with DAUNORUBICIN HCL (500 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (4380 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6816235-4 | Blood Glucose Increased
Patient was taking Cytarabine (View Usage). Patient had the following side effects: blood glucose increased on Jul 02, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 33.51 lb, . Cytarabine dosage: 384 Mg. During the same period patient was treated with DEXAMETHASONE (84 Mg) (View Dexamethasone Review and Dexamethasone Label ), DOXORUBICIN HYDROCHLORIDE (48 Mg) (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), METHOTREXATE (36 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (PEGASPARGASE, ONCOSPAR) (1600 Unit) (View Peg-l Asparaginase (pegaspargase, Oncospar) Review and Peg-l Asparaginase (pegaspargase, Oncospar) Label ), VINCRISTINE SULFATE (1.6 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ).